AUS
NZ
UK
CA
USA
IND
Healthcare
Are Chimeric Therapeutics (ASX:CHM) Leading ASX 200?
April 27, 2026 01:37 PM AEST| By SamChimeric Therapeutics Ltd highlights biotech sector activity on the ASX, with clinical developments and healthcare innovation driving attention within Australian equities.
Healthcare Sector Update: Is Mach7 Technologies (ASX:M7T) on ASX 300 Radar?
April 27, 2026 01:27 PM AEST| By SamMach7 Technologies Ltd remains active in the ASX healthcare sector, focusing on enterprise imaging solutions and digital health systems within Australia’s evolving healthcare landscape.
ASX 300 Healthcare Stock Gains After Key FDA Nod
April 27, 2026 11:06 AM AEST| By SamClinuvel Pharmaceuticals gained attention after an FDA decision reinforced confidence in its lead therapy, highlighting the importance of regulatory developments for ASX healthcare stocks.
Why Is (ASX:PAR) Highlighted in ASX Healthcare Sector?
April 27, 2026 11:01 AM AEST| By SamBiotech company Paradigm Biopharmaceuticals advances capital raising efforts, highlighting funding strategies and ongoing activity within the ASX healthcare sector.
ASX Biotech Pause: Why Syntara Hit the Brakes Before Key Update
April 27, 2026 10:18 AM AEST| By SamSyntara has paused trading ahead of key FDA feedback on its lead drug, highlighting the importance of regulatory milestones in shaping biotech company progress and market sentiment.
ASX 200 Spotlight: Are PLS and PME Valuations Sending Signals?
April 25, 2026 12:02 PM AEST| By SamPilbara Minerals and Pro Medicus highlight contrasting valuation trends, reflecting differences between commodity-driven lithium exposure and high-growth healthcare technology within the Australian share market.
ASX 200 Healthcare Stock Sonic: Quiet Value Opportunity?
April 25, 2026 11:57 AM AEST| By SamSonic Healthcare’s stable revenue model and global presence highlight its role as a defensive ASX 200 stock, with valuation trends and sector dynamics drawing renewed market attention.
Why Is (ASX:RMD) Drawing Attention in 2026?
April 25, 2026 09:44 AM AEST| By SamResMed’s evolving business model, financial strength, and global reach highlight why it remains a key stock to watch within Australia’s healthcare sector in 2026.
What Is Driving Medical Developments’ Cash Flow Turnaround?
April 24, 2026 08:56 PM AEST| By SamMedical Developments International reports strong quarterly performance with positive cash flow, driven by Penthrox growth and European expansion, while managing respiratory challenges and global supply chain risks.
Insider Move Sparks Buzz Around Clarity Pharma Update
April 24, 2026 03:39 PM AEST| By Team Kalkine MediaInsider activity at Clarity Pharmaceuticals has sparked discussion, highlighting ownership trends, shifting sentiment, and broader sector dynamics within Australia’s evolving equities landscape.
ASX 200 Healthcare Focus: Medical Developments Gains
April 24, 2026 02:54 PM AEST| By SamMedical Developments gains attention within the ASX healthcare sector as Penthrox supports operational activity, reflecting broader demand for specialised medical solutions.
Artrya Ltd Advances in Medical AI with Strong Market Movement
April 24, 2026 02:54 PM AEST| By Team Kalkine MediaArtrya Ltd gains attention as AI-driven cardiac imaging platform Salix enhances clinical workflows, highlighting innovation within Australia’s healthcare and technology sector.
4DMedical’s ASX 200 Momentum: Is Growth Already Priced In?
April 24, 2026 02:44 PM AEST| By Team Kalkine MediaStrong commercial progress and rising attention highlight evolving valuation dynamics, reflecting how innovation and sentiment interact within Australia’s equity landscape and influence future growth expectations.
Why Is (ASX:EBR) Gaining Attention After TGA Fast-Track Path?
April 24, 2026 02:43 PM AEST| By Sam(ASX:EBR) moves closer to Australian approval after securing a faster regulatory pathway, highlighting innovation in wireless cardiac therapy and improved treatment access.
Why Is (ASX:MVP) Gaining Attention as Penthrox Strengthens Cash Flow?
April 24, 2026 02:25 PM AEST| By SamMedical Developments International shows improved cash flow and product demand, with European expansion and regulatory developments shaping future growth across its healthcare portfolio.
ASX Biotech Watch: Can Tetratherix’s Momentum Continue?
April 24, 2026 02:19 PM AEST| By SamTetratherix continues to progress across clinical trials, partnerships, and commercial readiness, highlighting its growing presence in the regenerative medicine and healthcare innovation sector.
Cochlear Outlook Cut Weighs on ASX 200 Healthcare
April 24, 2026 12:08 PM AEST| By SamCochlear’s revised outlook highlights healthcare sector sensitivity, with corporate updates influencing market sentiment and shaping activity across ASX-listed medical technology companies.
ASX 200 Shock Sell-Off: Are These Beaten-Down Stocks Stirring Again?
April 24, 2026 10:41 AM AEST| By Team Kalkine MediaMarket volatility has pressured key ASX stocks, with healthcare names like Cochlear drawing attention as sentiment shifts amid geopolitical uncertainty and evolving global conditions.
What Drives InteliCare’s Move Into Retirement Living?
April 23, 2026 09:35 PM AEST| By SamInteliCare expands into retirement living through a new agreement, highlighting growth opportunities, recurring revenue potential, and key financial and execution challenges in the evolving healthcare technology sector.
ASX Healthcare Sector Focus Within ASX 200 Featuring Select Tickers
April 23, 2026 09:14 PM AEST| By Team Kalkine MediaOverview of the ASX healthcare sector with company highlights, index positioning, and sector dynamics across major Australian indices and related market segments.
Advertise your brand on Kalkine Media